Silo Wellness Announces Latest Psychedelic Retreat Offerings
December 16, 2021
Ryan Allway December 16th, 2021 Psychedelics Montego Bay, Jamaica–(Newsfile Corp. – December 16, 2021) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or “the Company”), a leading global psychedelics company, today unveiled a new series of psilocybin-assisted wellness retreats for 2022. Set in Jamaica’s idyllic... Read more
NeonMind Announces DTC Eligibility
August 25, 2021
Ryan Allway August 25th, 2021 Psychedelics VANCOUVER, BC / ACCESSWIRE / August 25, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FFE:6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today that its common shares... Read more
Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan
July 21, 2021
The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia San Diego, California–(Newsfile Corp. – July 21, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet... Read more
Wake Network, Inc. and the Lieber Institute for Brain Development Announce Research Collaboration
July 21, 2021
Ryan Allway July 21st, 2021 Psychedelics July 21, 2021 – Wake Network, Inc., a global leader in psilocybin mushroom research, production and the developer of genomics-based integration therapies, is pleased to announce a collaboration with the Lieber Institute for Brain Development (the ” Lieber Institute “), a non-profit research Institution... Read more
Psyence Group Corporate Update
May 27, 2021
Ryan Allway May 27th, 2021 News, Psychedelics TORONTO, May 27, 2021 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and value creation namely: Psyence Production, Psyence Therapeutics and Psyence Function.... Read more
Ryan Allway May 25th, 2021 Psychedelics San Diego, California–(Newsfile Corp. – May 25, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) (“Tryp”), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with Alcami Corporation (“Alcami”),... Read more
Wake Network Successfully Completes First Legal Psilocybin Mushroom Import into The United States
May 20, 2021
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Nova Mentis Launches Autism Clinical Study
May 6, 2021
Ryan Allway May 6th, 2021 Psychedelics VANCOUVER, BC, May 6, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that its North American autism... Read more
Ryan Allway May 6th, 2021 Psychedelics VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has commenced the development of its... Read more
Silo Wellness Announces Intellectual Property Licensing Agreement of Psilocybin Nasal Spray in Colombia and Brazil
April 15, 2021
Ryan Allway April 15th, 2021 Psychedelics TORONTO, April 15, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness”) (CSE: SILO) (FRA:3K70), a wellness company in the psychedelics and functional mushroom marketplaces announced today that through its wholly-owned subsidiary, it has signed a binding Letter of Intent (LOI) for a... Read more
